Historical Valuation
4D Molecular Therapeutics Inc (FDMT) is now in the Fair zone, suggesting that its current forward PS ratio of 56.68 is considered Fairly compared with the five-year average of -5.82. The fair price of 4D Molecular Therapeutics Inc (FDMT) is between 3.37 to 23.08 according to relative valuation methord.
Relative Value
Fair Zone
3.37-23.08
Current Price：7.77
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
4D Molecular Therapeutics Inc (FDMT) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 1.82 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 2.12, the current P/B ratio is about -100.00% higher. 4D Molecular Therapeutics Inc (FDMT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -25.15%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -21.55% , the current FCF yield is about -100.00% lower.
P/B
Median3y
1.82
Median5y
2.12
FCF Yield
Median3y
-25.15
Median5y
-21.55
Competitors Valuation Multiple
AI Analysis for FDMT
The average P/S ratio for FDMT competitors is 9.45, providing a benchmark for relative valuation. 4D Molecular Therapeutics Inc Corp (FDMT.O) exhibits a P/S ratio of 56.68, which is 500% above the industry average. Given its robust revenue growth of -50.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for FDMT
1Y
3Y
5Y
Market capitalization of FDMT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of FDMT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is FDMT currently overvalued or undervalued?
4D Molecular Therapeutics Inc (FDMT) is now in the Fair zone, suggesting that its current forward PS ratio of 56.68 is considered Fairly compared with the five-year average of -5.82. The fair price of 4D Molecular Therapeutics Inc (FDMT) is between 3.37 to 23.08 according to relative valuation methord.
What is 4D Molecular Therapeutics Inc (FDMT) fair value?
FDMT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of 4D Molecular Therapeutics Inc (FDMT) is between 3.37 to 23.08 according to relative valuation methord.
How does FDMT's valuation metrics compare to the industry average?
The average P/S ratio for FDMT's competitors is 9.45, providing a benchmark for relative valuation. 4D Molecular Therapeutics Inc Corp (FDMT) exhibits a P/S ratio of 56.68, which is 500.00% above the industry average. Given its robust revenue growth of -50.00%, this premium appears unsustainable.
What is the current P/B ratio for 4D Molecular Therapeutics Inc (FDMT) as of Jan 09 2026?
As of Jan 09 2026, 4D Molecular Therapeutics Inc (FDMT) has a P/B ratio of 0.00. This indicates that the market values FDMT at 0.00 times its book value.
What is the current FCF Yield for 4D Molecular Therapeutics Inc (FDMT) as of Jan 09 2026?
As of Jan 09 2026, 4D Molecular Therapeutics Inc (FDMT) has a FCF Yield of 0.00%. This means that for every dollar of 4D Molecular Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for 4D Molecular Therapeutics Inc (FDMT) as of Jan 09 2026?
As of Jan 09 2026, 4D Molecular Therapeutics Inc (FDMT) has a Forward P/E ratio of -1.26. This means the market is willing to pay $-1.26 for every dollar of 4D Molecular Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for 4D Molecular Therapeutics Inc (FDMT) as of Jan 09 2026?
As of Jan 09 2026, 4D Molecular Therapeutics Inc (FDMT) has a Forward P/S ratio of 56.68. This means the market is valuing FDMT at $56.68 for every dollar of expected revenue over the next 12 months.